This clinical trial is for adult men who have metastatic prostate cancer. This trial has multiple arms, or portions. Participants will only take part in one portion of the study.
   
The purpose of the first portion of this study is to assess the safety and tolerability (good and bad effects) and how prostate cancer responds to two different doses of the investigational study drug ARV-766 in men with metastatic prostate cancer who have progressed on prior approved systemic therapies for disease like theirs.
   

This study is evaluating an alternative treatment for glucose control. The treatment is with a device called the EndoBarrier® System. It is an experimental device that may help to treat diabetes where medications, diet, and exercise alone have not achieved enough improvement.

The EndoBarrier® System is considered investigational which means it is not currently approved by the U.S. Food and Drug Administration (FDA).

This study is investigating Blinatumomab in combination with chemotherapy in patients with newly diagnosed standard risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the treatment of patients with localized B-Lymphoblastic Lymphoma (B-LLy).

Blinatumomab is an investigational drug which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).

The purpose of this study is to test the good and bad effects of a drug called M3814 in combination with the drug avelumab and radiation therapy for advanced/metastatic solid tumors and hepatobiliary malignancies.

This clinical trial is for adults who have metastatic breast cancer with a BRCA 1 or BRCA 2 mutation of the tumor detectable by blood or tumor tissue.
   

This clinical trial is for men and women who have a solid tumor cancer (not a blood cancer) that has worsened and has not responded to at least one prior cancer treatment. Participants’ tumor DNA must also have an error in one of the genes associated with the homologous recombination (HR) pathway including but not limited to BRCA1 or 2 (Breast Cancer 1 or 2).
   

This clinical trial is for men and women who have been diagnosed with colorectal cancer that has spread to their liver and are eligible for standard of care surgery to remove tumors in their liver.
   

This clinical trial is for men and women who have been diagnosed with an advanced type of multiple myeloma (MM) and their cancer has returned after taking 3 or more other cancer medications (this is called relapsing) or those medications did not work (this is called refractory). Other study sites are also enrolling patients who have non-Hodgkin’s lymphoma (NHL), but Weill Cornell Medicine is only enrolling participants who have multiple myeloma (MM).
   

The goal of this study is to better understand the biology underlying plasma cell disorders.

To accomplish this goal, we have created a database-biorepository which is being used by investigators at Weill Cornell Medicine and their collaborators. By studying the clinical course of patients with plasma cell disorders, and by performing basic laboratory studies using their tissue, we hope to improve patient care.

The purpose of this study is to better understand how well the medication REBYOTA is working to prevent recurrence of CDI (Clostridioides Difficile Infection) among adults following antibiotic treatment. The study also aims to understand patient-reported outcomes and health care utilization (e.g., doctors’ visits, and hospitalizations) after receiving REBYOTA. 

REBYOTA prevents recurrence of CDI among adults following antibiotic treatment and this drug is approved by the U.S. Food and Drug Administration (FDA).